Recent Updates
Recently added Catalysts
HCM Positive Sentiment Score: 70/100

Extraordinary General Meeting held on

Monday, March 31, 2025 1 min read
Key Takeaway: HUTCHMED (China) Limited successfully held its Extraordinary General Meeting on March 31, 2025. The primary resolution regarding the sale and purchase of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited was approved by shareholders, receiving 99.9745% votes in favor. This outcome indicates a solid consensus among shareholders about the company's strategic direction.

Market Sentiment Analysis

POSITIVE FACTORS

  • The ordinary resolution to approve transactions was passed with an overwhelming majority.
  • 99.9745% of votes were in favor, indicating strong shareholder support.
  • The meeting reflects proactive corporate governance and decision-making.

Full Press Release Details

Extraordinary General Meeting held on March 31, 2025 - Poll Results
Hong Kong, Shanghai, & Florham Park, NJ: Monday, March 31, 2025: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX:13) today announces that the ordinary resolution put to its Extraordinary General Meeting ("EGM") held on March 31, 2025 was duly passed.
Reference is made to the notice of EGM dated March 14, 2025 and the circular to shareholders dated March 14, 2025 (the "Circular") issued by the Company. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.
The poll results of the ordinary resolution were as follows:
Ordinary Resolution Number of Votes (%)* Passed by Shareholders
For Against Withheld #
To approve the transactions related to the sale and purchase of a total of 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited under various agreements, and all actions by the Company and/or its subsidiaries pursuant or incidental to such transactions. ^ 475,229,253 ( 99.9745 %) 121,270 ( 0.0255 %) 1,670 Yes
* Percentages rounded to 4 decimal places.
# A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a resolution.
^ The full text of the resolution is set out in the notice of EGM dated March 14, 2025.
Investor Enquiries +852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting - +44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
Brunswick - Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Freddy Crossley / Rupert Dearden +44 20 7886 2500
HSBC Joint Broker
Simon Alexander / Alina Vaskina / Arnav Kapoor +44 20 7991 8888
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500

Frequently Asked Questions

When was the Extraordinary General Meeting held?

The Extraordinary General Meeting was held on March 31, 2025.

What resolution was passed at the EGM?

The resolution approved the sale and purchase of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited.

What were the poll results for the resolution?

The resolution received 99.9745% votes in favor and 0.0255% against.

How many votes were withheld during the EGM?

A total of 1,670 votes were withheld at the Extraordinary General Meeting.

How can investors contact HUTCHMED for inquiries?

Investors can reach HUTCHMED at +852 2121 8200 or ir@hutch-med.com.

Tags: HCM Viatris Investor Conferences Healthcare HUTCHMED Shanghai Hutchison Pharmaceuticals shareholder meeting equity interest
Last updated: Mar 31, 2025